Menu
 
Research menu
Jump to menu

Publications:  Prof Timothy Warner

Crescente M, Armstrong PC, Kirkby NS, Edin ML, Chan MV, Lih FB, Jiao J, Maffucci T et al.(2020). Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin. The FASEB Journal
10.1096/fj.202000312R
Vulliamy P, Montague SJ, Gillespie S, Chan MV, Coupland LA, Andrews RK, Warner TD, Gardiner EE et al.(2020). Loss of GPVI and GPIbα contributes to trauma-induced platelet dysfunction in severely injured patients. Blood advances vol. 4, (12) 2623-2630.
10.1182/bloodadvances.2020001776
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65273
Armstrong P, Ferreira PM, Chan M, Lundberg Slingsby M, Crescente M, Shih C, Kirkby N, Hobbs A et al.(2020). Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti-platelet therapy. Journal of Thrombosis and Haemostasis
10.1111/jth.14826
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64692
Chan MV, Chen M-H, Barwari T, Huffman JE, Armstrong PC, Hwang S-J, Santer P, Wierer B et al.(2020). Platelet Reactivity in Individuals Over 65 Years Old Is not Modulated by Age. Circulation Research
10.1161/CIRCRESAHA.119.316324
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64756
Chan MV, Hayman MA, Sivapalaratnam S, Crescente M, Allan HE, Edin ML, Zeldin DC, Milne GL et al.(2020). Identification of a homozygous recessive variant in PTGS1 resulting in a congenital aspirin-like defect in platelet function. Haematologica
10.3324/haematol.2019.235895
Paterson GG, Young JM, Willson JA, Graham CJ, Dru RC, Lee EW, Torpey GS, Walmsley SR et al.(2020). Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and Haemostasis vol. 120, (2) 253-261.
10.1055/s-0039-3400305
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62736
Mitchell JA, Shala F, Elghazouli Y, Warner TD, Gaston-Massuet C, Crescente M, Armstrong PC, Herschman HR et al.(2019). Cell-Specific Gene Deletion Reveals the Antithrombotic Function of COX1 and Explains the Vascular COX1/Prostacyclin Paradox. Circulation Research vol. 125, (9) 847-854.
10.1161/CIRCRESAHA.119.314927
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61089
Vulliamy P, Gillespie S, Armstrong P, Allan H, Warner T, Brohi K(2019). Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. Proceedings of the National Academy of Sciences
10.1073/pnas.1904978116
https://qmro.qmul.ac.uk/xmlui/handle/123456789/59038
Houde M, Carrier E, Grandbois M, Bkaily G, Warner TD, Korporaal SJA, Van Eck M, D'Orleans-Juste P (2019). ALTERED INHIBITION OF PLATELET AGGREGATION IN HYPERCHOLEROLEMIA IN MICE AND HUMANS. ATHEROSCLEROSIS. vol. 287, E109-E110.
10.1016/j.atherosclerosis.2019.06.320
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65461
Patel D, Warner TD, Armstrong PC (2019). ICAM-1 contributes to the preferential binding of platelets to classical and intermediate monocyte subsets over neutrophils. BRITISH JOURNAL OF PHARMACOLOGY. Conference: Pharmacology 2018 from: 20/12/2018 to: 18/12/2018, vol. 176, 3038-3039.
10.1111/bph.14681
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63940
Mazi SI, Ahmetaj-Shala B, Warner TD, Mitchell JA, Kirkby NS (2019). Omic profiling in healthy volunteers taking celecoxib reveals novel biomarkers regulated by cyclooxygenase-2. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. vol. 85, 1628-1628.
Lucotti S, Cerutti C, Soyer M, Gil-Bernabé AM, Gomes AL, Allen PD, Smart S, Markelc B et al.(2019). Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/ thromboxane A<inf>2</inf>. Journal of Clinical Investigation vol. 129, (5) 1845-1862.
10.1172/JCI121985
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57277
Menke L, Marcone S, Allan H, Godson C, Warner T (2019). Dihomo-gamma-linolenic acid alters the proteomic releasate profile and reduces platelet reactivity. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. vol. 49, 132-132.
Crescente M, Menke L, Chan MV, Armstrong PC, Warner TD(2019). Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). British Journal of Pharmacology vol. 176, (8) 988-999.
10.1111/bph.14196
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55988
Allan HE, Ferreira PMF, Crescente M, Warner TD (2019). Platelet Activation Causes Vesicle Release and Loss of Mitochondria. CARDIOVASCULAR DRUGS AND THERAPY. vol. 33, 268-268.
Barwari T, Eminaga S, Mayr U, Lu R, Armstrong PC, Chan MV, Sahraei M, Fernández-Fuertes M et al.(2018). Inhibition of profibrotic microRNA-21 affects platelets and their releasate. JCI insight vol. 3, (21)
10.1172/jci.insight.123335
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49537
Warner T, Halford G, Watson S(2018). In celebration of Professor Gus Born's life, 29 July 1921 - 16 April 2018. Platelets vol. 29, (8) 743-743.
10.1080/09537104.2018.1535117
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49864
Knowles RB, Warner TD(2018). Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. Pharmacol Ther vol. 193, 83-90.
10.1016/j.pharmthera.2018.08.004
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55461
Mitchell JA, Knowles RB, Kirkby NS, Reed DM, Edin ML, White WE, Chan MV, Longhurst H et al.(2018). Letter by Mitchell et al Regarding Article, "Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment". Circulation research vol. 122, (10) e84-e85.
10.1161/CIRCRESAHA.118.312976
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39086
Chan MV, Leadbeater PD, Watson SP, Warner TD(2018). Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry. Platelets1-4.
10.1080/09537104.2018.1466388
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39405
Chan MV, Armstrong PC, Warner TD(2018). 96-well plate-based aggregometry. Platelets1-6.
10.1080/09537104.2018.1445838
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36591
Mitchell JA, Knowles RB, Kirkby NS, Reed DM, Edin ML, White WE, Chan MV, Longhurst H et al.(2018). Kidney transplantation in a patient lacking cytosolic phospholipase A<inf>2</inf> proves renal origins of urinary PGI-M and TX-M. Circulation Research vol. 122, (4) 555-559.
10.1161/CIRCRESAHA.117.312144
https://qmro.qmul.ac.uk/xmlui/handle/123456789/35143
Lundberg Slingsby MH, Gliemann L, Thrane M, Rytter N, Egelund J, CHAN MV, Armstrong PC, Warner TD et al.(2018). Platelet responses to pharmacological and physiological interventions in middle-aged men with different habitual physical activity levels. Acta Physiol (Oxf)
10.1111/apha.13028
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36395
VULLIAMY P, GILLESPIE S, ARMSTRONG P, CHAN M, DAVENPORT R, WARNER T, BROHI K (2017). Platelets Shift Towards a Procoagulant and Proin ammatory Phenotype at the Expense of Aggregation During Trauma Hemorrhage: a Potential Role of Extracellular Histones. Circulation. Conference: American Heart Association Scientific Sessions (Anaheim, CA) from: 11/11/2017 to: 15/11/2017, vol. e448-467,
10.1161/CIR.0000000000000546
Carrier É, Houde M, Grandbois M, Bkaily G, Warner TD, D'Orléans-Juste P(2017). Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. Can J Physiol Pharmacol vol. 95, (8) 954-960.
10.1139/cjpp-2017-0314
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58878
Unsworth AJ, Bye AP, Tannetta DS, Desborough MJR, Kriek N, Sage T, Allan HE, Crescente M et al.(2017). Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. Arterioscler Thromb Vasc Biol vol. 37, (8) 1482-1493.
10.1161/ATVBAHA.117.309135
https://qmro.qmul.ac.uk/xmlui/handle/123456789/34466
Crescente M, Armstrong PC, CHAN MV, Edin ML, Lih FB, Jiao J, Gaston-Massuet C, Cottrell GS et al. (2017). PLATELET COX-1 KNOCKOUT MOUSE AS A MODEL OF THE EFFECTS OF ASPIRIN IN THE CARDIOVASCULAR SYSTEM. HEART. Conference: BCS Annual Conference, ‘Cardiology at the Extremes' vol. 103, A108-A109.
10.1136/heartjnl-2017-311726.146
Knowles RB, Lawrence MJ, Ferreira PM, Hayman MA, D'Silva LA, Stanford SN, Sabra A, Tucker AT et al.(2017). Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties. Platelets1-9.
10.1080/09537104.2017.1306039
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23469
Hayman M, Armstrong P, Chan M, Warner T (2017). Functional Analyses of Reticulated Platelets. FASEB JOURNAL. vol. 31,
Ahmetaj-Shala B, Tesfai A, Constantinou C, Leszczynski R, Chan MV, Gashaw H, Galaris G, Mazi S et al.(2017). Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. Biochemical and Biophysical Research Communications vol. 484, (4) 762-766.
10.1016/j.bbrc.2017.01.161
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23476
ARMSTRONG PCJ, hoefer T, knowles RB, Tucker AT, Hayman MA, Ferreira PM, Chan MV, Warner TD(2017). Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology
10.1161/ATVBAHA.116.308763
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22140
Watson SP, Daly ME, Harrison P, Lowe GC, Paterson A, Rivera J, Warner TD, Morgan NV(2016). ISTH Advanced Training Course on platelet bleeding disorders: How should they be investigated?: St. Anne’s College, Oxford, 6–9<sup>th</sup> September 2016. Platelets vol. 27, (8) 719-721.
10.1080/09537104.2016.1256726
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25973
Mitchell JA, Knowles R, Kirkby NS, Reed DM, White W, Edin ML, Longhurst H, Yaqoob M et al. (2016). Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A(2) Leads to Urinary Prostacyclin and Thromboxane A(2) Metabolites Within Normal Ranges. CIRCULATION. vol. 134,
Rauzi F, Kirkby NS, Edin ML, Whiteford J, Zeldin DC, Mitchell JA, Warner TD(2016). Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. The FASEB Journal
10.1096/fj.201600530R
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16583
Ferreira P, Armstrong P, Chan M, Warner T (2016). SOLUBLE GUANYLATE CYCLASE ACTIVATORS AS COMBINATION ANTI-PLATELET THERAPY WITH P2Y12 INHIBITORS AND PDE INHIBITORS: IN VIVO AND EX VIVO STUDIES. HEART. vol. 102, A118-A119.
10.1136/heartjnl-2016-309890.169
Hinz C, Aldrovandi M, Uhlson C, Marnett LJ, Longhurst HJ, Warner TD, Alam S, Slatter DA et al.(2016). Human platelets utilize cycloxygenase-1 to generate dioxolane A3, a neutrophil activating eicosanoid. Journal of Biological Chemistry Article jbc.M115.700609,
10.1074/jbc.M115.700609
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55554
Knowles R, D'Silva L, Stanford S, Armstrong P, Chan M, Tucker A, Ferreira P, Sabra A et al. (2016). INSIGHTS INTO THE ROLE OF PLATELETS IN FIBRIN CLOT FORMATION AND THE EFFICACY OF ANTI-PLATELET THERAPIES. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. vol. 67, 2127-2127.
10.1016/S0735-1097(16)32128-3
Chan MV, Knowles RBM, Lundberg MH, Tucker AT, Mohamed NA, Kirkby NS, Armstrong PCJ, Mitchell JA et al.(2016). P2Y<inf>12</inf> receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. British Journal of Clinical Pharmacology vol. 81, (4) 621-633.
10.1111/bcp.12826
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23621
Warner TD, Armstrong PC, Chan MV, Knowles RB(2016). The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. Expert Review of Hematology vol. 9, (3) 223-225.
10.1586/17474086.2016.1140035
Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K et al.(2016). Association of MicroRNAs and YRNAs with platelet function. Circulation Research vol. 118, (3) 420-432.
10.1161/CIRCRESAHA.114.305663
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23128
Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL et al.(2015). Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. FASEB J vol. 29, (11) 4568-4578.
10.1096/fj.15-275065
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25229
Ahmetaj-Shala B, Kirkby NS, Knowles R, Al'Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie LS et al.(2015). Reply to letter regarding article, "evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: Novel explanation of cardiovascular side effects associated with anti-inflammatory drugs". Circulation vol. 132, (17) e213-e214.
10.1161/CIRCULATIONAHA.115.017260
https://qmro.qmul.ac.uk/xmlui/handle/123456789/28913
Khanna V, Armstrong PCJ, Warner TD, Curzen N(2015). Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. Platelets vol. 26, (7) 689-692.
10.3109/09537104.2014.1001832
Armstrong PCJ, Kirkby NS, Chan MV, Finsterbusch M, Hogg N, Nourshargh S, Warner TD(2015). Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood vol. 126, (10) e11-e18.
10.1182/blood-2015-01-621656
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15669
Rauzi F, Kirkby N, Edin M, Zeldin D, Whiteford J, Mitchell J, Warner T (2015). 15(S)-HETE is a pro-angiogenic factor produced by platelets through COX-1. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 13, 225-225.
Armstrong PC, Warner TD (2015). Characterising cell-type interactions following platelet activation in a novel low volume whole blood assay. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 13, 657-657.
Knowles R, Chan M, Hayman M, Armstrong P, Tucker A, Timmis A, Warner T (2015). THE ANTI-PLATELET EFFECTIVENESS OF P2Y12 RECEPTOR BLOCKADE IS STRONGLY INFLUENCED BY THE ENDOTHELIUM- DERIVED MEDIATORS NITRIC OXIDE AND PROSTACYCLIN. HEART. vol. 101, A90-A91.
Knowles RB, Chan MV, Armstrong PC, Shih C-C, Hayman MA, Vojnovic I, Tucker AT, Timmis AD et al. (2015). The effectiveness of P2Y12 receptor blockade is strongly determined by the presence of endothelial Mediators prostacyclin and nitric oxide. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 13, 784-784.
Rull G, Mohd-Zain Z, Shiel J, Lundberg MH, Collier DJ, Johnston A, Warner TD, Corder R(2015). Effects of High Flavanol Dark Chocolate on Cardiovascular Function and Platelet Aggregation. Vascular pharmacology
10.1016/j.vph.2015.02.010
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7566
Ahmetaj-Shala B, Kirkby NS, Knowles R, Al'Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie L et al.(2015). Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugs. CIRCULATION vol. 131, (7) 633-U113.
10.1161/CIRCULATIONAHA.114.011591
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9590
Hoefer T, Armstrong PC, Finsterbusch M, Chan MV, Kirkby NS, Warner TD(2015). Drug-free platelets can act as seeds for aggregate formation during antiplatelet therapy. Arteriosclerosis, Thrombosis, and Vascular Biology vol. 35, (10) 2122-2133.
10.1161/ATVBAHA.115.306219
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9199
Floyd CN, Ferro A, Warner TD(2015). Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovasc Dis vol. 4,
10.1177/2048004015610252
Ross CL, Galloway-Phillipps N, Armstrong PC, Mitchell JA, Warner TD, Brearley C, Ito M, Tunstall T et al.(2015). Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: Monitoring the nasal and systemic immune response using a network biology approach. BMJ Open vol. 5, (1)
10.1136/bmjopen-2014-005750
Bender L, Mayr M, Kaudewitz D, Skroblin P, Willeit P, Morton A, Gracio F, Dudek K et al. (2014). PLASMA MICRORNA LEVELS IN PATIENTS WITH ACUTE CORONARY SYNDROME ARE ASSOCIATED WITH PLATELET FUNCTION. ATHEROSCLEROSIS. vol. 237, E5-E5.
10.1016/j.atherosclerosis.2014.10.044
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6574
Knowles RB, Chan MV, Armstrong PC, Shih C-C, Hayman MA, Vojnovic I, Tucker AT, Timmis AD et al. (2014). The Effectiveness of P2Y12 Receptor Antagonist Therapy is Strongly Determined by Endothelial Mediators of Platelet Function. CIRCULATION. vol. 130,
Lordkipanidze M, Lowe GC, Kirkby NS, Chan MV, Lundberg MH, Morgan NV, Bem D, Nisar SP et al.(2014). Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. BLOOD vol. 123, (8) E11-E22.
10.1182/blood-2013-08-520387
Kirkby NS, Lundberg MH, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA(2014). COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One vol. 9, (6)
10.1371/journal.pone.0098165
Brooke MA, Longhurst HJ, Plagnol V, Kirkby NS, Mitchell JA, Rüschendorf F, Warner TD, Kelsell DP et al.(2014). Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. Gut vol. 63, (1) 96-104.
10.1136/gutjnl-2012-303581
Lordkipanidze M, Chan MV, Lowe GC, Dawood BB, Warner TD, Watson SP, Grp UKGAPPS (2013). Head-to-head comparison of the optimul assay (96-well plate aggregometry) with gold standard light transmission aggregometry for detection of acquired and inherited platelet defects. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 11, 43-44.
Kirkhy NS, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA (2013). COX-2 and Cardiovascular Risk; Identification of New COX-2 Targets and Pathways Outside the Vessel Wall. CIRCULATION. vol. 128,
Ahmetaj-Shala B, Kirkby NS, Al-yamani M, Warner TD, Leiper J, Mitchell JA (2013). Evidence That Links Cyclo-oxygenase-2 Inhibition With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-inflammatory Drugs. CIRCULATION. vol. 128,
10.1161/CIRCULATIONAHA.114.011591
Kaudewitz D, Lee R, Willeit P, Zampetaki A, Morton AC, Warner TD, Storey RF, Channon K et al. (2013). Impact of Medication on Quantification of Plasma MicroRNAs in Patients With Cardiovascular Disease. CIRCULATION. vol. 128,
Kirkby NS, Chan MV, Lundberg MH, Massey KA, Edmands WMB, Mackenzie LS, Holmes E, Nicolaou A et al.(2013). Aspirin-triggered 15-epi-lipoxin A<inf>4</inf> predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: Implications for a clinical test. FASEB Journal vol. 27, (10) 3938-3946.
10.1096/fj.12-215533
Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD(2013). Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A vol. 110, (39) 15782-15787.
10.1073/pnas.1218880110
Bianca RDDV, Mitidieri E, Di Minno MND, Kirkby NS, Warner TD, Di Minno G, Cirino G, Sorrentino R(2013). Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 110, (39) 15812-15817.
10.1073/pnas.1309049110
Bianca RDEDV, Mitidieri E, Di Minno MND, Kirkby NS, Warner TD, Di Minno G, Cirino G, Sorrentino R (2013). The hydrogen sulfide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. NITRIC OXIDE-BIOLOGY AND CHEMISTRY. vol. 31, S24-S25.
10.1016/j.niox.2013.06.043
Kirkby NS, Zaiss AK, Wright WR, Jiao J, Chan MV, Warner TD, Herschman HR, Mitchell JA(2013). Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. Biochem Biophys Res Commun vol. 438, (2) 249-256.
10.1016/j.bbrc.2013.07.006
Floyd CN, Warner TD, Ferro A (2013). Comparison of the optimul assay with light transmission aggregometry for the detection of aspirin resistance in patients with stable coronary artery disease. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 11, 643-643.
Hoefer T, Warner TD (2013). DURING ANTI-PLATELET THERAPY PLATELET TURNOVER MAY LEAD TO THE EMERGENCE OF A MINORITY OF UNINHIBITED PLATELETS SUFFICIENT TO INITIATE AND DRIVE PLATELET AGGREGATE FORMATION. HEART. vol. 99,
10.1136/heartjnl-2013-304019.236
Lundberg MH, Kirkby NS, Mitchell JA, Warner TD (2013). P2Y12 INHIBITION GREATLY POTENTIATES THE ANTI-PLATELET EFFECTS OF PROSTACYCLIN AND NITRIC OXIDE. HEART. vol. 99, A137-U630.
10.1136/heartjnl-2013-304019.261
Willeit P, Zampetaki A, Kaudewitz D, Lee R, Dudek K, King A, Kirkby NS, Markus HS et al. (2013). PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION. HEART. vol. 99,
10.1136/heartjnl-2013-304019.265
Rauzi F, Kirkby NS, Edin M, Mitchell JA, Zeldin D, Warner TD (2013). PLATELET COX-1 SUPPORTS THE PRODUCTION OF BOTH PROSTANOIDS AND HETES. HEART. vol. 99, A114-A114.
10.1136/heartjnl-2013-304019.207
Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Warner TD, Nicolaou A, Herschman HR et al. (2013). Cox2 reporter gene expression and prostacylin mass spectrometry confirm vascular COX-1 dominance for prostacyclin production. FASEB JOURNAL. vol. 27,
Bjorkman J-A, Zachrisson H, Forsberg G-B, von Bahr H, Hansson GI, Warner TD, Nylander S(2013). High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y(12) inhibition. THROMBOSIS RESEARCH vol. 131, (4) 313-319.
10.1016/j.thromres.2013.01.029
Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M et al.(2013). Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. CIRCULATION RESEARCH vol. 112, (4) 595-+.
10.1161/CIRCRESAHA.111.300539
Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PDM, Milne GL, Potter CMF, Al-Yamani M, Adeyemi O et al.(2013). Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system (vol 109, pg 17597, 2012). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 110, (4) 1561-1561.
10.1073/pnas.1220901110
Mitchell JA, Warner TD(2013). Reply to Ricciotti et al.: Evidence for vascular COX isoforms. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 110, (3) E184-E184.
10.1073/pnas.1219532110
Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS et al.(2013). LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One vol. 8, (7)
10.1371/journal.pone.0069524
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5242
Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PDM, Milne GL, Potter CMF, Al-Yamani M, Adeyemi O et al.(2012). Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 109, (43) 17597-17602.
10.1073/pnas.1209192109
Mitidieri E, Bianca RDDV, Kirkby N, Warner TD, Cirino G, Sorrentino R (2012). L-Cysteine/H2S pathway involvement in human platelet aggregation. NITRIC OXIDE-BIOLOGY AND CHEMISTRY. vol. 27, S31-S32.
10.1016/j.niox.2012.08.045
Warner TD, Paul-Clark M, Mitchell JA(2012). Smoking, atherothrombosis and clopidogrel. Heart vol. 98, (13) 963-964.
10.1136/heartjnl-2012-301903
Warner TD, Mitchell JA, Kirkby NS(2012). Short thromboelastography and the identification of high platelet reactivity while on and off therapy. Heart vol. 98, (9) 679-680.
10.1136/heartjnl-2012-301676
Swales KE, Moore R, Truss NJ, Tucker A, Warner TD, Negishi M, Bishop-Bailey D(2012). Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc Res vol. 93, (4) 674-681.
10.1093/cvr/cvr330
Mcloughlin TF, Chan MV, Warner TD, Hart DP (2012). Validation of a novel, high-throughput platelet aggregation technique. HAEMOPHILIA. vol. 18, 18-19.
Andersson T, Morrison D, Nagy P, Pisupati J, Schettler J, Warner TD(2012). Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81 mg With or Without Esomeprazole 20 mg in Healthy Volunteers. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS vol. 12, (4) 217-224.
10.1007/BF03261830
Chan MV, Warner TD(2012). Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. Platelets vol. 23, (5) 404-408.
10.3109/09537104.2011.603066
Sambu N, Dent H, Warner T, Englyst N, Leadbeater P, Hobson A, Calver A, Corbett S et al. (2011). Stopping Clopidogrel 1 year After Drug-Eluting Stent (DES) Implantation: Is It Safe?. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. vol. 58, B41-B41.
Truss NJ, Warner TD(2011). Gasotransmitters and platelets. Pharmacol Ther vol. 132, (2) 196-203.
10.1016/j.pharmthera.2011.07.001
Warner TD, Nylander S, Whatling C(2011). Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol vol. 72, (4) 619-633.
10.1111/j.1365-2125.2011.03943.x
Kirkby NS, Leadbeater PDM, Chan MV, Nylander S, Mitchell JA, Warner TD(2011). Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost vol. 9, (10) 2103-2105.
10.1111/j.1538-7836.2011.04453.x
https://qmro.qmul.ac.uk/xmlui/handle/123456789/45164
Leadbeater PDM, Kirkby NS, Thomas S, Dhanji A-R, Tucker AT, Milne GL, Mitchell JA, Warner TD(2011). Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost vol. 9, (10) 2050-2056.
10.1111/j.1538-7836.2011.04450.x
Sambu N, Dent H, Englyst N, Warner TD, Leadbeater P, Roderick P, Gray H, Simpson I et al.(2011). Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. HEART vol. 97, (20) 1661-1667.
10.1136/heartjnl-2011-300192
Kirkby NS, Leadbeater PDM, Chan MV, Nylander S, Mitchell JA, Warner TD (2011). Aspirin augments the anti-platelet effects of partial but not complete P2Y(12) receptor blockade by ticagrelor. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 9, 780-780.
Kirkby NS, Singhal R, Mitchell JA, Warner TD (2011). Synergistic inhibition of platelet aggregation by nitric oxide and prostacyclin is potentiated by P2Y(12) blockade. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 9, 780-781.
Leadbeater PDM, Mitchell JA, Warner TD (2011). The effect of stir-speed and time on TP-receptor induced platelet aggregation in the presence of aspirin and P2Y(12) receptor blockade. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 9, 779-780.
Leadbeater PDM, Farndale RW, Mitchell JA, Warner TD (2011). The effect of stir-speed on GPVI-dependent platelet aggregation. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 9, 528-529.
Leadbeater PDM, Mitchell JA, Warner TD (2011). The effect of time on platelet aggregation assessed by light transmission. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. vol. 9, 779-779.
Kirkby NS, Harrington LS, Lundberg MH, Hoefer T, Warner TD, Mitchell JA (2011). CONTRIBUTION OF COX1 AND COX2 TO PROSTACYCLIN RELEASE BY HEALTHY MOUSE TISSUES. INFLAMMATION RESEARCH. vol. 60, 116-117.
Wright WR, Kirkby NS, Harrington LS, Lundberg MH, Paul-Clark MJ, Warner TD, Mitchell JA (2011). ROLE OF COX-1 AND COX-2 IN THE RELEASE OF PROSTANOIDS IN MURINE LUNG AND ISOLATED LUNG FIBROBLASTS. INFLAMMATION RESEARCH. vol. 60, 232-232.
Sambu N, Dent H, Warner T, Englyst N, Leadbeater P, Hobson A, Calver A, Corbett S et al. (2011). WHAT HAPPENS TO PLATELET FUNCTION AND VASCULAR INFLAMMATION WHEN CLOPIDOGREL IS WITHDRAWN? INSIGHTS USING SHORT THROMBELASTOGRAPHY. HEART. vol. 97, A16-A16.
10.1136/heartjnl-2011-300198.20
Armstrong PCJ, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD(2011). In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost vol. 9, (3) 552-561.
10.1111/j.1538-7836.2010.04160.x
Sambu N, Warner T, Curzen N(2011). Clopidogrel withdrawal: Is there a "rebound" phenomenon?. THROMB HAEMOSTASIS vol. 105, (2) 211-220.
10.1160/TH10-08-0554
Potter CMF, Lundberg MH, Harrington LS, Warboys CM, Warner TD, Berson RE, Moshkov AV, Gorelik J et al.(2011). Role of Shear Stress in Endothelial Cell Morphology and Expression of Cyclooxygenase Isoforms. ARTERIOSCL THROM VAS vol. 31, (2) 384-U314.
10.1161/ATVBAHA.110.214031
Warner TD(2011). What is the best dose of aspirin in association with P2Y12 antagonists? reply. HEART vol. 97, (3) 264-264.
10.1136/hrt.2010.216820
Huang RY, Li MY, Hsin MKY, Underwood MJ, Ma LT, Mok TSK, Warner TD, Chen GG(2011). 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor. ONCOGENE vol. 30, (1) 106-116.
10.1038/onc.2010.390
Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, Edin ML, Zeldin DC et al.(2011). Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One vol. 6, (10)
10.1371/journal.pone.0026591
https://qmro.qmul.ac.uk/xmlui/handle/123456789/2302
Chan MV, Armstrong PCJ, Papalia F, Kirkby NS, Warner TD(2011). Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets vol. 22, (7) 485-494.
10.3109/09537104.2011.592958
Armstrong PC, Kirkby NS, Zain ZN, Emerson M, Mitchell JA, Warner TD(2011). Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One vol. 6, (5)
10.1371/journal.pone.0020062
https://qmro.qmul.ac.uk/xmlui/handle/123456789/4749
Warner TD, Bjorkman J-A, Zachrisson H, Nylander S (2010). Acetylsalicylic Acid (ASA) Adds Limited Additional Antiplatelet Effect When Given in Addition to High-Level P2y(12) Receptor Inhibition and Can Increase Peripheral Vascular Resistance. CIRCULATION. vol. 122,
Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, Morrison AJ, Cobb AJA et al.(2010). Trapping of palindromic ligands within native transthyretin prevents amyloid formation. P NATL ACAD SCI USA vol. 107, (47) 20483-20488.
10.1073/pnas.1008255107
Warner TD, Armstrong PCJ, Curzen NP, Mitchell JA(2010). Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?. Heart vol. 96, (21) 1693-1694.
10.1136/hrt.2010.205724
Moreno L, McMaster SK, Gatheral T, Bailey LK, Harrington LS, Cartwright N, Armstrong PCJ, Warner TD et al.(2010). Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. BRIT J PHARMACOL vol. 160, (8) 1997-2007.
10.1111/j.1476-5381.2010.00814.x
Leadbeater P, Pathan N, Paul-Clark M, Warner T, Mitchell J (2010). Serum lipoteichoic acid in paediatric patients undergoing surgery with cardiopulmonary bypass. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. vol. 70, 293-293.
Shinhmar S, Truss N, Armstrong P, Vojnovic I, Warner T (2010). Use of a 96-well plate method for the determination of the anti-platelet effectiveness of a novel NO releasing aspirin molecule. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. vol. 70, 303-303.
Armstrong PCJ, Dhanji A-RA, Tucker AT, Mitchell JA, Warner TD(2010). Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost vol. 8, (3) 613-615.
10.1111/j.1538-7836.2009.03714.x
Vessillier S, Duchene J, Vojnovic I, Cipollone F, Mezzetti A, White S, Ahluwalia A, Bishop-Bailey D et al. (2009). THERAPEUTIC TARGETTING OF ATHEROSCLEROTIC PLAQUES WITH LATENT INTERLEUKIN-4. HEART. vol. 95,
10.1136/hrt.2009.178129h
Armstrong PCJ, Dhanji AA, Tucker AT, Mitchell JA, Warner TD (2009). URINARY 11-DEHYDRO-THROMBOXANE B2 AS A MARKER OF THE ANTI-PLATELET EFFECTS OF CLOPIDOGREL OR ASPIRIN THERAPY IN HEALTHY MALE VOLUNTEERS. HEART. vol. 95,
10.1136/hrt.2009.178137a
Truss NJ, Armstrong PCJ, Liverani E, Vojnovic I, Warner TD(2009). Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. J Thromb Haemost vol. 7, (11) 1897-1905.
10.1111/j.1538-7836.2009.03589.x
Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA(2009). PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report. Arterioscler Thromb Vasc Biol vol. 29, (11) 1871-1873.
10.1161/ATVBAHA.109.193367
Leung KC, Hsin MKY, Chan JSY, Yip JHY, Li MY, Leung BCS, Mok TSK, Warner TD et al.(2009). Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. EXP CELL RES vol. 315, (17) 2974-2981.
10.1016/j.yexcr.2009.06.025
Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, Miller-Degraff L, Bradbury JA, Holness MJ et al.(2009). The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PLoS One vol. 4, (10)
10.1371/journal.pone.0007421
Armstrong PCJ, Dhanji A-R, Truss NJ, Zain ZNM, Tucker AT, Mitchell JA, Warner TD(2009). Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost vol. 102, (4) 772-778.
10.1160/TH09-04-0215
Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G et al.(2009). Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. J IMMUNOL vol. 183, (3) 2089-2096.
10.4049/jimmunol.0900477
Truss NJ, Beavis J, Maccallum PK, Harrison P, Warner TD(2009). Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96-well microtiter plates. J THROMB HAEMOST vol. 7, (7) 1226-1228.
10.1111/j.1538-7836.2009.03466.x
Ali FY, Armstrong PCJ, Dhanji A-RA, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD(2009). Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol vol. 29, (5) 706-711.
10.1161/ATVBAHA.108.183160
Armstrong PCJ, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZNM, Bishop-Bailey D, Paul-Clark MJ et al.(2008). Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost vol. 6, (11) 1933-1943.
10.1111/j.1538-7836.2008.03133.x
Harrington LS, Lucas R, McMaster SK, Moreno L, Scadding G, Warner TD, Mitchell JA(2008). COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J vol. 22, (11) 4005-4010.
10.1096/fj.08-107979
Ali FY, Warner TD, Mitchell JA (2008). Comparison of responses in IP and PPAR beta deleted murine platelets. HEART. vol. 94,
Zain ZNM, Armstrong PCJ, Pearson NJ, Mitchell JA, Warner TD (2008). Evaluation of aspirin inhibition of platelet aggregation induced by combination of collagen and adrenaline in a 96-well plate format. HEART. vol. 94,
Dhanji AA, Truss NJ, Bishop-Bailey D, Shipolini A, Mitchell JA, Warner TD (2008). Generation of clonal populations of prostaglandin I-2-producing rat vascular smooth muscle cells: Potential utility for production of bypass vessels. HEART. vol. 94,
Armstrong PCJ, Zain ZNM, Truss NJ, Vojnovic I, Bishop-Bailey D, Mitchell JA, Warner TD (2008). Linear relationship between platelet aggregation and thromboxane A(2) production. HEART. vol. 94,
Truss NJ, Armstrong PCJ, Zain ZN, Ali FY, Warner TD (2008). Platelet aggregation after storage of whole blood at 4 degrees C. HEART. vol. 94,
Vessillier S, Duchene J, Vojnovic I, Ahluwalia A, Bishop-Bailey D, Chernajovsky Y, Warner TD (2008). Stabilisation of atherosclerotic plaques: The latent targeting cytokines strategy. HEART. vol. 94,
Boesen EI, Sasser JM, Saleh MA, Potter WA, Woods M, Warner TD, Pollock JS, Pollock DM(2008). Interleukin-1 beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. AM J PHYSIOL-RENAL vol. 295, (2) F446-F453.
10.1152/ajprenal.00095.2008
Papalia F, Armstrong PCJ, Pearson NJ, Zain ZNM, Ali FY, Vojnovic I, Warner TD (2008). Development of a routine test of platelet reactivity. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. vol. 65, 979-979.
Aboud Z, Misra S, Warner T, Miall P, Benjamin N, Hobbs A, Webb A, Ahluwalia A (2008). The enterosalivary bioconversion of nitrate to nitrite underlies the blood pressure (BP) lowering and anti-platelet effects of a dietary nitrate load. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. vol. 65, 999-999.
Warner TD, Mitchell JA(2008). COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. LANCET vol. 371, (9608) 270-273.
10.1016/S0140-6736(08)60137-3
Truss NJ, Warner TD(2008). Gases help fuel the vascular debate. EXP PHYSIOL vol. 93, (1) 139-140.
10.1113/expphysiol.2007.038455
Li YTY, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D(2007). Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol vol. 27, (12) 2606-2611.
10.1161/ATVBAHA.107.152694
Patel TA, Belcher E, Warner TD, Harding SE, Mitchell JA(2007). Identification and characterization of a dysfunctional cardiac myocyte phenotype: Role of bacteria, toll-like receptors, and endothelin. SHOCK vol. 28, (4) 434-440.
10.1097/shk.0b013e31804a55a7
Piqueras L, Norlyng L, Perretti M, Li Y, Sanz MJ, Real JT, Warner T, Bishop-Bayley D (2007). PPARb inhibits neutrophil-endothelium interactions under flow. INFLAMM RES. vol. 56, S453-S454.
Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, Bishop-Bailey D(2007). Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood vol. 109, (9) 3741-3744.
10.1182/blood-2006-05-022566
Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD et al.(2007). Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol vol. 27, (1) 63-69.
10.1161/01.ATV.0000250972.83623.61
Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD(2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J vol. 20, (14) 2468-2475.
10.1096/fj.06-6615com
Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D(2006). The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res vol. 66, (20) 10120-10126.
10.1158/0008-5472.CAN-06-2399
Perez-Vizcaino F, Bishop-Bailley D, Lodi F, Duarte J, Cogolludo A, Moreno L, Bosca L, Mitchell JA et al.(2006). The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochem Biophys Res Commun vol. 346, (3) 919-925.
10.1016/j.bbrc.2006.05.198
Patel TA, Mitchell JA, Warner TD, Harding SE (2006). Gram positive bacteria reduce viability and contraction of isolated cardiomyocytes: Role of endothelin-1. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY. vol. 40, 1007-1007.
10.1016/j.yjmcc.2006.03.254
Bishop-Bailey D, Mitchell JA, Warner TD(2006). COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol vol. 26, (5) 956-958.
10.1161/01.ATV.0000219672.68024.bc
Chen GG, Lee TW, Yip JHY, Xu H, Lee IKY, Mok TSK, Warner TD, Yim APC(2006). Increased thromboxane B-2 levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. CANCER LETT vol. 234, (2) 193-198.
10.1016/j.canlet.2005.03.032
Warner TD, Vojnovic I, Bishop-Bailey D, Mitchell JA(2006). Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J vol. 20, (3) 542-544.
10.1096/fj.05-4434fje
Burke SG, Wainwright CL, Vojnovic I, Warner T, Watson DG, Furman BL(2006). The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat. J PHARMACOL EXP THER vol. 316, (3) 1107-1114.
10.1124/jpet.105.096339
Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA(2006). Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR beta. FASEB J vol. 20, (2) 326-328.
10.1096/fj.05-4395fje
Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA(2006). Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J vol. 20, (2) 326-328.
10.1096/fj.05-4395fje
Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA(2006). Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol vol. 34, (2) 242-246.
10.1165/rcmb.2005-0289OC
Mitchell JA, Warner TD(2006). COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. NAT REV DRUG DISCOV vol. 5, (1) 75-85.
10.1038/nrd1929
Li MY, Lee TW, Mok TSK, Warner TD, Yim APC, Chen GG(2005). Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J CELL BIOCHEM vol. 96, (4) 760-774.
10.1002/jcb.20474
Piqueras L, Warner TD, Bishop-Bailey D (2005). Expression of peroxisome proliferators-activator receptor-delta and retinoid X receptors in endothelial cells. HEART. vol. 91,
Haque ME, Moraes LA, Warner TD, Bishop-Bailey D (2005). Farnesoid X receptor ligands inhibited human platelet aggregation induced by ADP. HEART. vol. 91,
Wray JA, Williams NP, Warner TD, Bishop-Bailey D (2005). PPAR-alpha activation downregulates COX-2 expression in human monocytes. HEART. vol. 91,
Moraes LA, Warner TD, Bishop-Bailey D (2005). Retinoid X receptor ligands inhibit human platelet aggregation induced by ADP and U46619. HEART. vol. 91,
Jimenez R, Belcher E, Sriskandan S, Lucas R, McMaster S, Vojnovic L, Warner TD, Mitchell JA(2005). Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. P NATL ACAD SCI USA vol. 102, (12) 4637-4642.
10.1073/pnas.0407655101
Lucas R, Warner TD, Vojnovic I, Mitchell JA(2005). Cellular mechanisms of acetaminophen: role of cyclooxygenase. FASEB J vol. 19, (2) 635-+.
10.1096/fj.04-2437fje
Zacharowski P, Breese E, Wood E, Del Soldato P, Warner T, Mitchell J(2005). NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. Eur J Pharmacol vol. 508, (1-3) 7-13.
10.1016/j.ejphar.2004.11.064
Mitchell JA, Warner TD(2005). Discontinuation of Vioxx. LANCET vol. 365, (9453) 27-28.
10.1016/S0140-6736(04)17659-9
Warner T, Ali F, Bishop-Bailey D, Mitchell J, Moraes L (2005). Influences of nuclear receptors on platelet. JOURNAL OF VASCULAR RESEARCH. vol. 42, 24-25.
Rao M, Yang W, Bishop-Bailey D, Warner TD, Seifalian AM, Winslet MC (2004). Roles of cyclo-oxygenase 2 and prostanoids in the development of liver metastases from colorectal cancer. BRITISH JOURNAL OF SURGERY. vol. 91, 1230-1230.
Warner TD, Vojnovic I, Giuliano F, Jiménez R, Bishop-Bailey D, Mitchell JA(2004). Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J Pharmacol Exp Ther vol. 310, (2) 642-647.
10.1124/jpet.103.063875
Warner TD, Mitchell JA(2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J vol. 18, (7) 790-804.
10.1096/fj.03-0645rev
Sasser JM, Woods M, Warner TD, Pollock DM, Pollock JS (2004). Role of nuclear factor-kappa B in interleukin-1 beta stimulated endothelin-1 release in inner medullary collecting duct cells. FASEB JOURNAL. vol. 18, A1322-A1322.
Bishop-Bailey D, Walsh DT, Warner TD(2004). Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A vol. 101, (10) 3668-3673.
10.1073/pnas.0400046101
Warner TD, Mitchell JA(2003). HIF, stretching to get control of VEGF. Clin Sci (Lond) vol. 105, (4) 393-394.
10.1042/CS20030208
Bishop-Bailey D, Warner TD(2003). PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J vol. 17, (13) 1925-1927.
10.1096/fj.02-1075fje
Woods M, Wood EG, Bardswell SC, Bishop-Bailey D, Barker S, Wort SJ, Mitchell JA, Warner TD(2003). Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol vol. 64, (4) 923-931.
10.1124/mol.64.4.923
Jimenez R, Warner TD, Belcher PE, Vojnovic I, Mitchell JA (2003). Induction of NOSII and COX activity in primary cultures of murine smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY. vol. 140,
Warner TD, Mitchell JA(2003). Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC?. Proc Natl Acad Sci U S A vol. 100, (16) 9108-9110.
10.1073/pnas.1733826100
Wray J, Zeldin D, Warner TD, Bishop-Bailey D (2003). Cytochrome P450 2J2 over-expression activates peroxisome proliferator-activated receptor-alpha. BRITISH JOURNAL OF PHARMACOLOGY. vol. 138, U85-U85.
Bishop-Bailey D, Walsh DT, Warner TD (2003). Farnesoid X receptor (FXR) as a novel target in vascular smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY. vol. 138, U30-U30.
Walters MJ, Warner TD, Bishop-Bailey D, Mitchell JA (2003). The PPAR gamma ligand 15-deoxy-Delta(12,14)-prostaglandin J(2) (15D-PGJ(2)) inhibits proliferation and cytokine release from human pulmonary artery smooth muscle. BRITISH JOURNAL OF PHARMACOLOGY. vol. 138, U66-U66.
Thomas MA, Bishop-Bailey D, Warner TD (2003). The novel CO releasing compound tricarbonyldichlororuthenium (II) dimer confers protection from free radical mediated cytotoxicity in WKY 3M-22 cell line and primary rat aortic smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY. vol. 138, U84-U84.
Thomas MA, Warner TD, Bishop-Bailey D (2003). The novel CO releasing compound Tricarbonyldichlororuthenium (11) dimer protects H9C2 rat cardiomyoblasts from free radical mediated cytotoxicity. FASEB JOURNAL. vol. 17, A618-A619.
Gray PA, Warner TD, Vojnovic I, Del Soldato P, Parikh A, Scadding GK, Mitchell JA(2002). Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol vol. 137, (7) 1031-1038.
10.1038/sj.bjp.0704927
Giuliano F, Warner TD(2002). Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther vol. 303, (3) 1001-1006.
10.1124/jpet.102.041244
Calatayud S, Warner TD, Breese EJ, Mitchell JA(2002). Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. CYTOKINE vol. 20, (4) 163-167.
10.1006/cyto.2002.1999
Warner TD, Mitchell JA, Vane JR(2002). Cyclo-oxygenase-2 inhibitors and cardiovascular events. LANCET vol. 360, (9346) 1700-1701.
10.1016/S0140-6736(02)11635-7
Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA(2002). Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol vol. 62, (5) 1147-1153.
10.1124/mol.62.5.1147
Warner TD, Mitchell JA(2002). Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?. Proc Natl Acad Sci U S A vol. 99, (21) 13371-13373.
10.1073/pnas.222543099
McCartney SA, Ballinger AB, Vojnovic I, Farthing MJG, Warner TD(2002). Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci vol. 71, (16) 1893-1904.
10.1016/s0024-3205(02)01923-9
Bishop-Bailey D, Hla T, Warner TD(2002). Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res vol. 91, (3) 210-217.
10.1161/01.res.0000029080.15742.85
Sims EC, Rothman MT, Warner TD, Powell MEB(2002). Coronary artery brachytherapy. CLIN ONCOL-UK vol. 14, (4) 313-326.
10.1053/clon.2002.0070
McCartney SA, Greaves RRSH, Warner TD, O'Donnell LJD, Domizio P, Farthing MJG(2002). Endothelin content, expression, and receptor type in normal and diseased human gallbladder. Dig Dis Sci vol. 47, (8) 1786-1792.
10.1023/a:1016532228836
Burke SG, Furman BL, Wainwright CL, Del Soldato P, Vojnovic I, Warner T(2002). The effect of no-aspirin on arrhythmias & infarct size in hearts isolated from the SHR. J MOL CELL CARDIOL vol. 34, (6) A14-A14.
10.1016/S0022-2828(02)90780-7
Calatayud S, Warner TD, Mitchell JA(2002). Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. BRIT J CANCER vol. 86, (8) 1316-1321.
10.1038/sj/bjc/6600240
Calatayud S, Mitchell JA, Perretti M, Giuliano F, Warner TD(2002). Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. EUR J PHARMACOL vol. 440, (1) 71-77.
10.1016/s0014-2999(02)01342-0
Woods M, Wood EG, Mitchell JA, Bishop-Bailey D, Warner TD (2002). Antisense to STAT1/IRF-1 and NF-kappa B inhibits cytokine-stimulated ET-1 release from human vascular smooth muscle cells. BRIT J PHARMACOL. vol. 135,
Thomas MA, Bishop-Bailey D, Warner TD (2002). Heme oxygenase induction is associated with protection from SIN-1 cytotoxicity in WKY 3M-22 rat aortic smooth muscle cells. BRIT J PHARMACOL. vol. 135,
Giuliano F, Vojnovic L, Warner TD (2002). Prostacyclin production from intact pat blood vessels is via the activity of cyclooxygenase-1 as defined by naproxen, paracetamol, rofecoxib and SC560. BRIT J PHARMACOL. vol. 135,
Burke SG, Furman BL, Wainwright CL, Del Soldato P, Vojnovic I, Warner T (2002). The effect of NO-aspirin on arrhythmias and infarct size in isolated spontaneously hypertensive rat hearts. BRIT J PHARMACOL. vol. 135,
Zacharowski K, Rensing H, Frank S, Warner TD (2002). Doses of bacterial wall fragment of S-aureus that induce delayed preconditioning do not induce heme oxygenase-1 and inducible nitric oxide synthase. BRIT J PHARMACOL. vol. 135,
Gray PA, Vojnovic I, Del Soldato P, Mitchell JA, Warner TD (2002). Effects of plasma proteins and blood elements on the potencies of flurbiprofen and NO-flurbiprofen as inhibitors of thromboxane A(2) formation by human platelets. BRIT J PHARMACOL. vol. 135,
Kvirkvelia N, Vojnovic I, Warner TD, Athie-Morales V, Free P, Rayment N, Chain BM, Rademacher TW et al.(2002). Placentally derived prostaglandin E-2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. CLIN EXP IMMUNOL vol. 127, (2) 263-269.
10.1046/j.1365-2249.2002.01718.x
Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA(2002). Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol vol. 21, (2) 93-101.
Warner T(2002). Valdecoxib - A viewpoint by Tim Warner. DRUGS vol. 62, (14) 2072-2073.
10.2165/00003495-200262140-00007
Giuliano F, Mitchell JA, Warner TD(2001). Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. J Pharmacol Exp Ther vol. 299, (3) 894-900.
Calatayud S, Warner TD, Breese EJ, Mitchell JA (2001). Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. BRIT J PHARMACOL. vol. 134, 1237-1244.
10.1038/sj.bjp.0704358
Zacharowski K, Thomas M, Wood EG, Bishop-Bailey D, Warner TD (2001). Cardioprotective effect of PPAR gamma receptor agonist rosiglitazone is abolished by cycloheximid or dexamethasone. CIRCULATION. vol. 104, 53-53.
Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD(2001). Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol vol. 426, (1-2) 95-103.
10.1016/s0014-2999(01)01207-9
Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA(2001). Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation - Relevance to pathogenesis of pulmonary hypertension and vascular remodeling. AM J RESP CELL MOL vol. 25, (1) 104-110.
10.1165/ajrcmb.25.1.4331
Sims EC, Powell MEB, Rothman MT, Warner TD (2001). Targeted radioimmunotherapy - Novel delivery of coronary artery radiation. BRIT J CANCER. vol. 85, 17-17.
Caliendo G, Santagada V, Perissutti E, Severino B, Fiorino F, Warner TD, Wallace JL, Ifa DR et al.(2001). Synthesis of substituted benzamides as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 but do not cause gastric damage. EUR J MED CHEM vol. 36, (6) 517-530.
10.1016/s0223-5234(01)01251-x
Thomas MA, Bishop-Bailey D, Wood EG, Warner TD (2001). Biliverdin, the product of heme oxygenase metabolism attenuates SIN-1 induced apoptosis in WKY 3M-22 rat aortic smooth muscle cells. BRIT J PHARMACOL. vol. 133, U62-U62.
Giuliano F, Warner TD (2001). COX-1-derived PGE(2): A comparison between human and rat blood. BRIT J PHARMACOL. vol. 133, U101-U101.
Calatayud S, Allcock GH, Perretti M, Mitchell JA, Warner TD (2001). Comparison of the effects of the selective COX-2 inhibitor, DFP, and indomethacin on leukocyte-endothelial cell interactions in the rat mesentery. BRIT J PHARMACOL. vol. 133, U102-U102.
Bardswell SC, Woods M, Bishop-Bailey D, Wood EG, Mitchell JA, Warner TD (2001). Effect of peroxisome proliferator-activated receptor agonists on cytokine-stimulated endothelin-1 production in human vascular smooth muscle cells. BRIT J PHARMACOL. vol. 133, U52-U52.
Calatayud S, Warner TD, Mitchell JA (2001). Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. BRIT J PHARMACOL. vol. 133, U126-U126.
Bishop-Bailey D, Hla T, Warner TD (2001). Peroxisome proliferator-activated (PPAR) gamma ligands induce vascular smooth muscle cell apoptosis. BRIT J PHARMACOL. vol. 133, U18-U18.
Gray PA, Breese EJ, Wood EG, Warner TD, Mitchell JA (2001). Respective effects of cAMP elevation versus cGMP elevation on GMCSF release by human synoviocytes. BRIT J PHARMACOL. vol. 133, U21-U21.
Price S, Warner TD, Evans TW, Anning PB, Mitchell JA (2001). Role of endothelin-1 in modulation of cardiac function in endotoxaemia. BRIT J PHARMACOL. vol. 133, U4-U4.
Warner TD(2001). Introduction to "nimesulide: beyond COX-2". Clin Exp Rheumatol vol. 19, (1 Suppl 22) S1-S2.
Bennett A, Warner TD(2001). Nimesulide: Beyond COX-2 - EULAR Satellite Symposium (22 June 2000) - Foreword. CLIN EXP RHEUMATOL vol. 19, (1) II-II.
Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA(2001). Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax vol. 56, (1) 30-35.
10.1136/thorax.56.1.30
Roland MA, Patel I, Roberts NJ, Sapsford RJ, Warner T, Wedzicha JA (2000). The effect of clarithromycin on endothelin-1 production by primary bronchial epithelial cell cultures from COPD patients. THORAX. vol. 55, A6-A6.
Woods M, Wood EG, Mitchell JA, Warner TD (2000). Cyclic AMP regulates cytokine stimulation of endothelin-1 release in human vascular smooth muscle cells. J Cardiovasc Pharmacol. vol. 36, S404-S406.
10.1097/00005344-200036051-00118
Woods M, Wood EG, Mitchell JA, Warner TD (2000). Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol. vol. 36, S407-S409.
10.1097/00005344-200036051-00119
Wort SJ, Mitchell JA, Woods M, Evans TW, Warner TD (2000). The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells. J Cardiovasc Pharmacol. vol. 36, S410-S413.
10.1097/00005344-200036051-00120
Vane JR, Warner TD(2000). Nomenclature for COX-2 inhibitors. Lancet vol. 356, (9239) 1373-1374.
10.1016/s0140-6736(00)02837-3
Bishop-Bailey D, Hla T, Warner TD(2000). Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. Br J Pharmacol vol. 131, (4) 651-654.
10.1038/sj.bjp.0703628
Chen G, Wang SH, Warner TD(2000). Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. Free Radic Res vol. 32, (3) 223-234.
10.1080/10715760000300231
Mitchell JA, Gray P, Anning PD, Woods M, Warner TD, Evans TW(2000). Effects of nitric oxide-modulating amino acids on coronary vessels: relevance to sepsis. Eur J Pharmacol vol. 389, (2-3) 209-215.
10.1016/s0014-2999(99)00837-7
Mitchell JA, Warner TD(1999). Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol vol. 128, (6) 1121-1132.
10.1038/sj.bjp.0702897
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR(1999). Nonsteroid drug selectives for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis (vol 96, pg 7563, 1999). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 96, (17) 9966-9966.
Hamilton LC, Vojnovic I, Warner TD(1999). A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol vol. 127, (7) 1589-1596.
10.1038/sj.bjp.0702708
Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F et al.(1999). Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) vol. 38, (8) 779-788.
10.1093/rheumatology/38.8.779
McCartney SA, Mitchell JA, Fairclough PD, Farthing MJ, Warner TD(1999). Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther vol. 13, (8) 1115-1117.
10.1046/j.1365-2036.1999.00585.x
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR(1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A vol. 96, (13) 7563-7568.
10.1073/pnas.96.13.7563
Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD(1999). Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol vol. 55, (5) 902-909.
Giuliano F, Warner TD(1999). Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol vol. 126, (8) 1824-1830.
10.1038/sj.bjp.0702518
Saunders MA, Belvisi MG, Cirino G, Barnes PJ, Warner TD, Mitchell JA(1999). Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. J Pharmacol Exp Ther vol. 288, (3) 1101-1106.
Warner TD (1999). Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol. vol. 26, 247-252.
10.1046/j.1440-1681.1999.03025.x
Hamilton LC, Mitchell JA, Tomlinson AM, Warner TD(1999). Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy. FASEB J vol. 13, (2) 245-251.
10.1096/fasebj.13.2.245
Chen G, Wood EG, Wang SH, Warner TD(1999). Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor-kappaB activation. Life Sci vol. 64, (14) 1231-1242.
10.1016/s0024-3205(99)00055-7
Hamilton LC, Warner TD(1998). Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib. Br J Pharmacol vol. 125, (2) 335-340.
10.1038/sj.bjp.0702077
Chen G, Kamal M, Hannon R, Warner TD(1998). Regulation of cyclo-oxygenase gene expression in rat smooth muscle cells by catalase. Biochem Pharmacol vol. 55, (10) 1621-1631.
10.1016/s0006-2952(98)00021-5
Warner TD, McCartney SA(1998). NOS inhibitors in colitis: a suitable case for treatment?. Gut vol. 42, (2) 152-153.
10.1136/gut.42.2.152
D'Amico M, Di Filippo C, Rossi F, Warner TD(1998). Role of AT2 receptors in the cardiovascular events following microinjection of angiotensin II into the superior colliculus of anaesthetised rats. Naunyn Schmiedebergs Arch Pharmacol vol. 357, (2) 121-125.
10.1007/pl00005145
Woods M, Bishop-Bailey D, Pepper JR, Evans TW, Mitchell JA, Warner TD(1998). Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells. J Cardiovasc Pharmacol vol. 31 Suppl 1, S348-S350.
10.1097/00005344-199800001-00097
D'Amico M, Rossi F, Warner TD(1997). Regulation of blood pressure by L-arginine-nitric oxide pathway within the superior colliculus of rats. Eur J Pharmacol vol. 328, (1) 65-67.
10.1016/s0014-2999(97)83029-4
Chen G, Warner TD(1997). A single competitive reverse transcriptase-polymerase chain reaction assay to measure inducible nitric oxide synthase gene expression in both human and rat. Anal Biochem vol. 247, (2) 455-458.
10.1006/abio.1997.2046
Bishop-Bailey D, Larkin SW, Warner TD, Chen G, Mitchell JA(1997). Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol vol. 121, (1) 125-133.
10.1038/sj.bjp.0701100
Takahashi T, Barnes PJ, Kawikova I, Yacoub MH, Warner TD, Belvisi MG(1997). Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. Eur J Pharmacol vol. 324, (2-3) 219-222.
10.1016/s0014-2999(97)10008-5
Allcock GH, Warner TD(1997). Activation of ETa receptors is partially responsible for the rapid increase in haematocrit induced by bacterial lipopolysaccharide in the rat. LIFE SCIENCES vol. 60, (19) PL271-PL276.
10.1016/S0024-3205(97)00116-1
D'Amico M, Rossi F, Warner TD(1996). Cardiovascular responses induced by injection of endothelin-1 into the superior colliculus of rats. Eur J Pharmacol vol. 316, (2-3) 245-247.
10.1016/s0014-2999(96)00778-9
Warner TD(1996). Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. Int Angiol vol. 15, (2) 93-99.
Warner TD, Elliott JD, Ohlstein EH(1996). California dreamin' 'bout endothelin: emerging new therapeutics. Trends Pharmacol Sci vol. 17, (5) 177-181.
10.1016/0165-6147(96)30006-0
D'Amico M, Dashwood MR, Warner TD(1996). Endothelin-1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study. Br J Pharmacol vol. 118, (1) 21-26.
10.1111/j.1476-5381.1996.tb15361.x
Warner TD, Klemm P(1996). What turns on the endothelins?. Inflamm Res vol. 45, (2) 51-53.
10.1007/BF02265115
D'Amico M, Warner TD(1995). Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. Br J Pharmacol vol. 116, (7) 2787-2789.
10.1111/j.1476-5381.1995.tb15927.x
Hohlfeld T, Klemm P, Thiemermann C, Warner TD, Schrör K, Vane JR(1995). The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol vol. 116, (8) 3309-3315.
10.1111/j.1476-5381.1995.tb15140.x
Allcock GH, Warner TD, Vane JR(1995). Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists. Br J Pharmacol vol. 116, (5) 2482-2486.
10.1111/j.1476-5381.1995.tb15099.x
Allcock GH, Battistini B, Fournier A, Warner TD, Vane JR(1995). Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. J Pharmacol Exp Ther vol. 275, (1) 120-126.
Berthiaume N, Claing A, Regoli D, Warner TD, D'Orléans-Juste P(1995). Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. Br J Pharmacol vol. 115, (7) 1319-1325.
10.1111/j.1476-5381.1995.tb15043.x
Battistini B, Botting R, Warner TD(1995). Endothelin: a knockout in London. Trends Pharmacol Sci vol. 16, (7) 217-222.
10.1016/s0165-6147(00)89029-x
Goto K, Warner TD(1995). Molecular pharmacology. Endothelin versatility. Nature vol. 375, (6532) 539-540.
10.1038/375539a0
Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR(1995). Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol vol. 114, (7) 1335-1342.
10.1111/j.1476-5381.1995.tb13353.x
Bryant CE, Allcock GH, Warner TD(1995). Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. Br J Pharmacol vol. 114, (8) 1673-1679.
10.1111/j.1476-5381.1995.tb14956.x
Battistini B, Woods M, O'Donnell LJ, Warner TD, Corder R, Fournier A, Farthing MJ, Vane JR(1995). Contractile activity of endothelin precursors in the isolated gallbladder of the guinea-pig: presence of an endothelin-converting enzyme. Br J Pharmacol vol. 114, (7) 1383-1390.
10.1111/j.1476-5381.1995.tb13359.x
Klemm P, Warner TD, Willis D, Moore AR, Vane JR(1995). Coronary vasoconstriction in vitro in the hearts of polyarthritic rats: effectiveness of in vivo treatment with the endothelin receptor antagonist SB 209670. Br J Pharmacol vol. 114, (7) 1327-1328.
10.1111/j.1476-5381.1995.tb13351.x
COOPER AC, PEREZVIZCAINO F, CORDER R, FOURNIER A, WARNER TD (1995). RAPID DEGRADATION OF ENDOTHELIN-1 BY AN ENZYME RELEASED BY THE RAT ISOLATED-PERFUSED MESENTERY. BRITISH JOURNAL OF PHARMACOLOGY. vol. 114, P197-P197.
Klemm P, Warner TD, Hohlfeld T, Corder R, Vane JR(1995). Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc Natl Acad Sci U S A vol. 92, (7) 2691-2695.
10.1073/pnas.92.7.2691
Pérez-Vizcaíno F, Cooper AC, Corder R, Fournier A, Warner TD(1995). Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. Br J Pharmacol vol. 114, (4) 867-871.
10.1111/j.1476-5381.1995.tb13284.x
Klemm P, Warner TD, Corder R, Vane JR(1995). Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J Cardiovasc Pharmacol vol. 26 Suppl 3, S419-S421.
Kengatharan M, Battistini B, Warner TD, Thiemermann C, Vane JR (1995). Endothelin-1 mediates the increase in ex vivo coronary vascular resistance induced by hemorrhagic shock in the anesthetized rat. J Cardiovasc Pharmacol. vol. 26 Suppl 3, S422-S424.
Allcock GH, Warner TD (1995). Inhibition of ETB receptors limits the efficacy of nonselective endothelin antagonists in vivo. J Cardiovasc Pharmacol. vol. 26 Suppl 3, S177-S179.
Desai KM, Warner TD, Bishop AE, Polak JM, Vane JR(1994). Nitric oxide, and not vasoactive intestinal peptide, as the main neurotransmitter of vagally induced relaxation of the guinea pig stomach. Br J Pharmacol vol. 113, (4) 1197-1202.
10.1111/j.1476-5381.1994.tb17124.x
Warner TD, Battistini B, Doherty AM, Corder R(1994). Endothelin receptor antagonists: actions and rationale for their development. Biochem Pharmacol vol. 48, (4) 625-635.
10.1016/0006-2952(94)90038-8
Battistini B, O'Donnell LJ, Warner TD, Fournier A, Farthing MJ, Vane JR(1994). Characterization of endothelin (ET) receptors in the isolated gall bladder of the guinea-pig: evidence for an additional ET receptor subtype. Br J Pharmacol vol. 112, (4) 1244-1250.
10.1111/j.1476-5381.1994.tb13217.x
Warner TD, Allcock GH, Vane JR(1994). Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol vol. 112, (1) 207-213.
10.1111/j.1476-5381.1994.tb13053.x
Korbut R, Warner TD, Gryglewski RJ, Vane JR(1994). The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. Br J Pharmacol vol. 112, (1) 289-291.
10.1111/j.1476-5381.1994.tb13066.x
Macarthur H, Warner TD, Wood EG, Corder R, Vane JR(1994). Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun vol. 200, (1) 395-400.
10.1006/bbrc.1994.1462
MOYNIHAN HA, ROBERTS SM, WELDON H, ALLCOCK GH, ANGGARD EE, WARNER TD(1994). SYNTHESIS AND BIOLOGICAL-ACTIVITY OF THE NOVEL NITRIC-OXIDE SYNTHASE INHIBITOR N-(OMEGA')-HYDROXY-N-(OMEGA)-METHYL-L-ARGININE. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1 (7) 769-771.
10.1039/p19940000769
Battistini B, Warner TD, Fournier A, Vane JR(1994). Characterization of ETB receptors mediating contractions induced by endothelin-1 or IRL 1620 in guinea-pig isolated airways: effects of BQ-123, FR139317 or PD 145065. Br J Pharmacol vol. 111, (4) 1009-1016.
10.1111/j.1476-5381.1994.tb14844.x
Battistini B, Warner TD, Fournier A, Vane JR(1994). Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620. Eur J Pharmacol vol. 252, (3) 341-345.
10.1016/0014-2999(94)90184-8
Wellings RP, Corder R, Warner TD, Cristol JP, Thiemermann C, Vane JR(1994). Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br J Pharmacol vol. 111, (2) 515-520.
10.1111/j.1476-5381.1994.tb14767.x
Desai KM, Warner TD, Vane JR(1994). 5-HT3 receptors do not mediate vagally-induced relaxation or contraction of the isolated stomach of the guinea-pig. Br J Pharmacol vol. 111, (1) 346-350.
10.1111/j.1476-5381.1994.tb14066.x
WARNER TD(1994). ENDOTHELIN RECEPTOR ANTAGONISTS. CARDIOVASCULAR DRUG REVIEWS vol. 12, (2) 105-122.
10.1111/j.1527-3466.1994.tb00286.x
Warner TD, Battistini B, Allcock GH, Vane JR(1993). Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. Eur J Pharmacol vol. 250, (3) 447-453.
10.1016/0014-2999(93)90032-d
Warner TD (1993). Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. Eur Heart J. vol. 14 Suppl I, 42-47.
Warner TD, Allcock GH, Mickley EJ, Vane JR(1993). Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea-pig ileum. Br J Pharmacol vol. 110, (2) 783-789.
10.1111/j.1476-5381.1993.tb13880.x
D'Orléans-Juste P, Claing A, Warner TD, Yano M, Télémaque S(1993). Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. Br J Pharmacol vol. 110, (2) 687-692.
10.1111/j.1476-5381.1993.tb13866.x
Warner TD, Allcock GH, Corder R, Vane JR(1993). Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol vol. 110, (2) 777-782.
10.1111/j.1476-5381.1993.tb13879.x
MITCHELL JA, SWIERKOSZ TA, WARNER TD, GROSS S, THIEMERMANN C, VANE JR (1993). REGULATION OF PROSTACYCLIN SYNTHESIS BY THE RELEASE OF ENDOGENOUS NITRIC-OXIDE IN RESPONSE TO BACTERIAL LIPOPOLYSACCHARIDE. BRITISH JOURNAL OF PHARMACOLOGY. vol. 109, P4-P4.
Mitchell JA, Kohlhaas KL, Sorrentino R, Warner TD, Murad F, Vane JR(1993). Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. Br J Pharmacol vol. 109, (1) 265-270.
10.1111/j.1476-5381.1993.tb13563.x
Warner TD, Vane JR(1993). Pharmacology. ET touches down in Houston. Nature vol. 362, (6420) 497-498.
10.1038/362497a0
WELLINGS RP, WARNER TD, CORDER R, CRISTOL JP, THIEMERMANN C, VANE JR (1993). A NEW NONSELECTIVE ENDOTHELIN ANTAGONIST BLOCKS THE VASOCONSTRICTION INDUCED BY ENDOTHELIN-1 IN THE RAT-KIDNEY, BOTH INVIVO AND INVITRO. BRITISH JOURNAL OF PHARMACOLOGY. vol. 108, P110-P110.
Cristol JP, Warner TD, Thiemermann C, Vane JR(1993). Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol vol. 108, (3) 776-779.
10.1111/j.1476-5381.1993.tb12877.x
Warner TD, Allcock GH, Mickley EJ, Corder R, Vane JR(1993). Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol vol. 22 Suppl 8, S117-S120.
10.1097/00005344-199322008-00032
Kaw S, Warner TD, Vane JR (1993). The metabolism of endothelin-1 and big endothelin-1 by the isolated perfused kidney of the rabbit. J Cardiovasc Pharmacol. vol. 22 Suppl 8, S65-S68.
10.1097/00005344-199322008-00019
Wellings RP, Warner TD, Thiemermann C, Cristol JP, Corder R, Vane JR(1993). Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065. J Cardiovasc Pharmacol vol. 22 Suppl 8, S103-S106.
10.1097/00005344-199322008-00028
SCHMIDT H, WARNER TD, ISHII K, SHENG H, MURAD F(1992). NITRIC-OXIDE AND ARGININE-EVOKED INSULIN-SECRETION - RESPONSE. SCIENCE vol. 258, (5086) 1376-1378.
10.1126/science.258.5086.1376-a
Matsumoto T, Mitchell JA, Schmidt HH, Kohlhaas KL, Warner TD, Förstermann U, Murad F(1992). Nitric oxide synthase in ferret brain: localization and characterization. Br J Pharmacol vol. 107, (3) 849-852.
10.1111/j.1476-5381.1992.tb14535.x
WARNER TD, ALLCOCK GH, CORDER R, VANE JR (1992). BQ123 AND DIFFERENT ISOLATED TISSUE PREPARATIONS REVEAL HETEROGENEITY IN THE RECEPTORS MEDIATING CONTRACTIONS TO ENDOTHELIN-1. BRITISH JOURNAL OF PHARMACOLOGY. vol. 107, P103-P103.
Warner TD, Budzik GP, Matsumoto T, Mitchell JA, Förstermann U, Murad F(1992). Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA. Br J Pharmacol vol. 106, (4) 948-952.
10.1111/j.1476-5381.1992.tb14440.x
Warner TD, Schmidt HH, Kuk J, Mitchell JA, Murad F(1992). Human brain contains a metalloprotease that converts big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA. Br J Pharmacol vol. 106, (3) 505-506.
10.1111/j.1476-5381.1992.tb14364.x
Mitchell JA, Kohlhaas KL, Matsumoto T, Pollock JS, Förstermann U, Warner TD, Schmidt HH, Murad F(1992). Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages. Mol Pharmacol vol. 41, (6) 1163-1168.
WARNER TD, SCHMIDT H, MURAD F(1992). INTERACTIONS OF ENDOTHELINS AND EDRF IN BOVINE NATIVE ENDOTHELIAL-CELLS - SELECTIVE EFFECTS OF ENDOTHELIN-3. AMERICAN JOURNAL OF PHYSIOLOGY vol. 262, (5) H1600-H1605.
Schmidt HH, Warner TD, Murad F(1992). Double-edged role of endogenous nitric oxide. Lancet vol. 339, (8799)
10.1016/0140-6736(92)91556-n
Schmidt HH, Warner TD, Nakane M, Förstermann U, Murad F(1992). Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. Mol Pharmacol vol. 41, (4) 615-624.
Schmidt HH, Warner TD, Ishii K, Sheng H, Murad F(1992). Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science vol. 255, (5045) 721-723.
10.1126/science.1371193
Warner TD, Mitchell JA, D'Orleans-Juste P, Ishii K, Förstermann U, Murad F(1992). Characterization of endothelin-converting enzyme from endothelial cells and rat brain: detection of the formation of biologically active endothelin-1 by rapid bioassay. Mol Pharmacol vol. 41, (2) 399-403.
Mitchell JA, de Nucci G, Warner TD, Vane JR(1992). Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol vol. 105, (2) 485-489.
10.1111/j.1476-5381.1992.tb14280.x
Kaw S, Hecker M, Southan GJ, Warner TD, Vane JR (1992). Characterization of serine protease-derived metabolites of big endothelin in the cytosolic fraction from human polymorphonuclear leukocytes. J Cardiovasc Pharmacol. vol. 20 Suppl 12, S22-S24.
10.1097/00005344-199204002-00008
Warner TD, Budzik GP, Mitchell JA, Huang ZJ, Murad F (1992). Detection by bioassay and specific enzyme-linked immunosorbent assay of phosphoramidon-inhibitable endothelin-converting activity in brain and endothelium. J Cardiovasc Pharmacol. vol. 20 Suppl 12, S19-S21.
10.1097/00005344-199204002-00007
Murad F, Forstermann U, Nakane M, Schmidt H, Pollock J, Sheng H, Matsumoto T, Warner T et al.(1992). The nitric oxide-cyclic GMP signal transduction pathway in vascular smooth muscle preparations and other tissues. Jpn J Pharmacol vol. 58 Suppl 2, 150P-157P.
Ishii K, Warner TD, Sheng H, Murad F(1991). Endothelin increases cyclic GMP levels in LLC-PK1 porcine kidney epithelial cells via formation of an endothelium-derived relaxing factor-like substance. J Pharmacol Exp Ther vol. 259, (3) 1102-1108.
Pollock JS, Förstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, Murad F(1991). Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A vol. 88, (23) 10480-10484.
10.1073/pnas.88.23.10480
D'Orléans-Juste P, Claing A, Télémaque S, Warner TD, Regoli D(1991). Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. Eur J Pharmacol vol. 204, (3) 329-334.
10.1016/0014-2999(91)90860-s
Förstermann U, Schmidt HH, Pollock JS, Sheng H, Mitchell JA, Warner TD, Nakane M, Murad F(1991). Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem Pharmacol vol. 42, (10) 1849-1857.
10.1016/0006-2952(91)90581-o
Ishii K, Sheng H, Warner TD, Förstermann U, Murad F(1991). A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. Am J Physiol vol. 261, (2 Pt 2) H598-H603.
10.1152/ajpheart.1991.261.2.H598
Mitchell JA, de Nucci G, Warner TD, Vane JR(1991). Alkaline buffers release EDRF from bovine cultured aortic endothelial cells. Br J Pharmacol vol. 103, (2) 1295-1302.
10.1111/j.1476-5381.1991.tb09783.x
Mitchell JA, Förstermann U, Warner TD, Pollock JS, Schmidt HH, Heller M, Murad F(1991). Endothelial cells have a particulate enzyme system responsible for EDRF formation: measurement by vascular relaxation. Biochem Biophys Res Commun vol. 176, (3) 1417-1423.
10.1016/0006-291x(91)90444-c
NAKANE M, HARALD, SCHMIDT HHW, WARNER TD, HUANG ZJ, MURAD F (1991). INDUCTION OF TYPE-II GUANYLYL CYCLASE-ACTIVATING-FACTOR (GAF) SYNTHASE IN RAW MACROPHAGES REQUIRES TRANSCRIPTION AND DENOVO-PROTEIN BIOSYNTHESIS. FASEB JOURNAL. vol. 5, A509-A509.
Ishii K, Warner TD, Sheng H, Murad F(1991). Endothelin-1 stimulates cyclic GMP formation in porcine kidney epithelial cells via activation of the L-arginine-dependent soluble guanylate cyclase pathway. J Cardiovasc Pharmacol vol. 17 Suppl 7, S246-S250.
10.1097/00005344-199100177-00071
D'Orléans-Juste P, Lidbury PS, Telemaque S, Warner TD, Vane JR (1991). Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1. J Cardiovasc Pharmacol. vol. 17 Suppl 7, S251-S255.
10.1097/00005344-199100177-00072
Warner TD, D'Orleans-Juste P, Vane JR(1990). Endothelin-1 and U46619 potentiate selectively the venous responses to nerve stimulation within the perfused superior mesenteric vascular bed of the rat. Biochem Biophys Res Commun vol. 172, (2) 745-750.
10.1016/0006-291x(90)90737-8
D'Orléans-Juste P, Lidbury PS, Warner TD, Vane JR(1990). Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biochem Pharmacol vol. 39, (9) R21-R22.
10.1016/0006-2952(90)90419-l
Warner TD(1990). Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists. Br J Pharmacol vol. 99, (2) 427-433.
10.1111/j.1476-5381.1990.tb14720.x
Warner TD, de Nucci G, Vane JR(1989). Comparison of the survival of endothelium-derived relaxing factor and nitric oxide within the isolated perfused mesenteric arterial bed of the rat. Br J Pharmacol vol. 97, (3) 777-782.
10.1111/j.1476-5381.1989.tb12016.x
Warner TD, de Nucci G, Vane JR(1989). Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol vol. 159, (3) 325-326.
10.1016/0014-2999(89)90167-2
Warner TD, Mitchell JA, de Nucci G, Vane JR(1989). Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol vol. 13 Suppl 5, S85-S88.
10.1097/00005344-198900135-00021
de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR(1988). Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A vol. 85, (24) 9797-9800.
10.1073/pnas.85.24.9797
de Nucci G, Warner T, Vane JR(1988). Effect of captopril on the bradykinin-induced release of prostacyclin from guinea-pig lungs and bovine aortic endothelial cells. Br J Pharmacol vol. 95, (3) 783-788.
10.1111/j.1476-5381.1988.tb11705.x
DENUCCI G, MITCHELL JA, WARNER TD, BEARPARK T, VANE JR (1988). RELEASE OF EDRF AND PGI2 FROM BAEC INDUCED BY INFUSIONS OF ADP, BRADYKININ, ARACHIDONIC-ACID, L-ARGININE AND ALKALINE BUFFERS. BRITISH JOURNAL OF PHARMACOLOGY. vol. 95, P547-P547.
de Nucci G, Gryglewski RJ, Warner TD, Vane JR(1988). Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A vol. 85, (7) 2334-2338.
10.1073/pnas.85.7.2334
Return to top